Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Salburg, Austria Clinical Trials

A listing of Salburg, Austria clinical trials actively recruiting patients volunteers.

RESULTS

Found (7) clinical trials

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab

This is a phase 1b/2, multicenter, open-label, basket trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, gastroesophageal cancer (GEC), melanoma, NSCLC, RCC in Part 1 Group …

Phase

0.84 miles

Learn More »

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Phase

0.84 miles

Learn More »

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC).

Phase

0.84 miles

Learn More »

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

Phase

0.84 miles

Learn More »

Safety Tolerability Pharmacokinetics and Efficacy of AMG 160 in Subjects With mCRPC

This is a phase I, first-in-human study to evaluate the safety and tolerability of AMG 160; a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody construct, alone and in combination with pembrolizumab in subjects with metastatic castration-resistant prostate cancer.

Phase

0.84 miles

Learn More »

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) or Tafasitamab and Lenalidomide in addition to R-CHOP in adult patients with newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma (DLBCL).

Phase

0.84 miles

Learn More »

Study of AMG 199 in Subjects With MUC17-Positive Gastric and Gastroesophageal Junction Cancer

AMG 199 is a novel half-life extended (HLE) bispecific T cell engager (BiTE) molecule designed to direct T cells towards MUC17-expressing cells. This is a first-in-human study in adult subjects with MUC17-positive gastric cancer or gastroesophageal junction (GEJ) cancer, to assess AMG 199 safety, tolerability, pharmacokinetics (PK), and anti-tumor activity, …

Phase

0.84 miles

Learn More »